Overview

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Status:
Terminated
Trial end date:
2019-05-09
Target enrollment:
Participant gender:
Summary
The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabidiol (CBD) and a low concentration of THC (relative to average street cannabis) will be tested in order to maximize clinical efficacy while minimizing intoxicating side effects in this medically-ill population.
Phase:
Phase 1
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Temozolomide